Search Results - "Sando, Yasuhisa"

Refine Results
  1. 1
  2. 2

    Extending Treatment Intervals of R-CHOP Therapy Might Be Acceptable for Some Patients with Non-indolent Non-Hodgkin's B-cell Lymphoma by Fujishita, Keigo, Yasuhisa, Sando, Oka, Satoshi, Fujisawa, Yuka, Machida, Takuya, Imai, Toshi

    Published in Acta medica Okayama (01-02-2022)
    “…R-CHOP therapy is generally performed every 3 weeks. We investigated the effects of extending the interval of R-CHOP therapy for > 1 week on the prognoses of…”
    Get full text
    Journal Article
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8

    Long-term outcomes in patients treated in the intensive care unit after hematopoietic stem cell transplantation by Nakamura, Makoto, Fujii, Nobuharu, Shimizu, Kazuyoshi, Ikegawa, Shuntaro, Seike, Keisuke, Inomata, Tomoko, Sando, Yasuhisa, Fujii, Keiko, Nishimori, Hisakazu, Matsuoka, Ken-ichi, Morimatsu, Hiroshi, Maeda, Yoshinobu

    Published in International journal of hematology (01-12-2018)
    “…The number of patients who are successfully discharged from the intensive care unit (ICU) after hematopoietic stem cell transplantation (HSCT) remains limited…”
    Get full text
    Journal Article
  9. 9

    Chemotherapy Improved Pulmonary Arterial Hypertension in a Patient with Chronic-Active Epstein-Barr Virus Infection by Akagi, Satoshi, Miki, Takashi, Sando, Yasuhisa, Fujii, Nobuharu, Sarashina, Toshihiro, Nakamura, Kazufumi, Ito, Hiroshi

    Published in International Heart Journal (31-01-2020)
    “…Chronic-active Epstein-Barr virus infection (CAEBV) is a rare disease that can lead to pulmonary arterial hypertension (PAH). However, the treatment for…”
    Get full text
    Journal Article
  10. 10
  11. 11
  12. 12

    PTCy ameliorates GVHD by restoring regulatory and effector T-cell homeostasis in recipients with PD-1 blockade by Ikegawa, Shuntaro, Meguri, Yusuke, Kondo, Takumi, Sugiura, Hiroyuki, Sando, Yasuhisa, Nakamura, Makoto, Iwamoto, Miki, Maeda, Yoshinobu, Matsuoka, Ken-ichi

    Published in Blood advances (10-12-2019)
    “…Graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a significant cause of morbidity and mortality…”
    Get full text
    Journal Article
  13. 13
  14. 14
  15. 15
  16. 16

    Successful treatment with azacitidine for myelodysplastic syndrome with large vessel vasculitis by Mishima, Mai, Makita, Masanori, Sando, Yasuhisa, Yamamoto, Yoshikazu, Shiote, Yasuhiro, Hara, Yoshitaka, Yamamoto, Kazuhiko, Imajo, Kenji

    Published in Rinshō ketsueki (01-01-2015)
    “…Paraneoplastic inflammation of the large vessels is a rare complication of myelodysplastic syndrome (MDS), and patients with MDS and systemic vasculitis have a…”
    Get more information
    Journal Article
  17. 17
  18. 18

    Posttransplant Cyclophosphamide Promote Naïve-Subset Dominant B Cell Recovery Coordinated with Early Treg Expansion; Implication of Reduced Risk of Pathogenesis into Chronic Gvhd by Iwamoto, Miki, Meguri, Yusuke, Kondo, Takumi, Sugiura, Hiroyuki, Ikegawa, Shuntaro, Sando, Yasuhisa, Nakamura, Makoto, Maeda, Yoshinobu, Matsuoka, Ken-Ichi

    Published in Blood (29-11-2018)
    “…Posttransplant cyclophosphamide (PTCy) is an effective prophylaxis for both acute and chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic…”
    Get full text
    Journal Article
  19. 19

    Post-Transplant Cyclophosphamide Ameliorates Lethal Thymic GVHD By Restoring Regulatory and Effector T Cell Homeostasis in Recipients with Prior PD-1 Blockade Therapy by Ikegawa, Shuntaro, Meguri, Yusuke, Kondo, Takumi, Sugiura, Hiroyuki, Sando, Yasuhisa, Nakamura, Makoto, Iwamoto, Miki, Maeda, Yoshinobu, Matsuoka, Ken-Ichi

    Published in Blood (29-11-2018)
    “…Allogeneic HSCT has a curative potential for patients with hematological malignancies. However, graft-versus-host disease (GVHD) remains to be a significant…”
    Get full text
    Journal Article
  20. 20